M

Monte Rosa Therapeutics

Develops targeted protein degraders for therapy

Technology Specialist 1/2

System Administration +1Confirmed live in the last 24 hours
Full-timeBasel, SwitzerlandCHF80k - CHF105kIn-person

About the Job

Requirements

  • At least 3 years of hands-on IT support experience.
  • Working knowledge of Microsoft Intune, including Windows mobile device management, compliance, and patch management.
  • Working knowledge of macOS device management tools such as Addigy or Jamf.
  • Solid fundamentals in Windows and macOS administration, Active Directory and Entra ID concepts, and basic networking, including DNS, DHCP, VLANs, and Wi-Fi troubleshooting.
  • Experience in a fast-paced life sciences or biotechnology environment is desirable.

Responsibilities

  • Prototype and deploy lightweight automations, including scripts, Power Automate or similar tools, API integrations, and large language model or agentic workflows via internal tools, to reduce manual toil for scientific and G&A teams.
  • Act as a technology advocate and translator between the lab bench and IT, proactively surfacing tools, including AI copilots and agentic workflows, that improve throughput, data quality, or turnaround time.
  • Promote automation-first thinking and document reusable solutions rather than one-off fixes.
  • Serve as an escalation point and hands-on contributor for the IT Help Desk ticket queue, ensuring timely resolution and clear communication.
  • Provide in-person and remote support across Windows, macOS, mobile devices, and common SaaS and productivity tools, including Office 365, Okta, Zoom, Egnyte, and Atlassian Suite.
  • Support conference room audio/video, Zoom Rooms, and office technology for smooth hybrid collaboration.
  • Maintain and improve IT documentation, knowledge base articles, and self-service resources.

About the Company

Monte Rosa Therapeutics

Develops targeted protein degraders for therapy

Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to treat cancer and autoimmune/inflammatory diseases using its QuEEN discovery engine, a platform that fuses AI-guided chemistry, proteomics, and structural biology to design MGDs. MGDs work by bringing a target protein together with an E3 ligase, tagging the protein for destruction by the cell's proteasome rather than just inhibiting it. The company distinguishes itself with the QuEEN platform, partnerships with Roche and Novartis for joint development and funding, and a portfolio that includes MRT-2359, MRT-6160, and MRT-8102 as clinical-stage programs. Its goal is to discover, develop, and commercialize MGDs, grow its pipeline, and create value through collaborations, upfront payments, milestones, and royalties while delivering treatments for patients with serious diseases.

Company size
201-500
Company stage
IPO
Headquarters
Boston, MA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Monte Rosa Therapeutics

See more jobs